 |
市場調查報告書
商品編碼
2078889
品牌學名藥市場：依藥物類別、劑型、適應症、通路及地區分類Branded Generics Market, By Drug Class By Formulation, By Indication, Distribution Channel and By Region |
||||||
價格
簡介目錄
預計到2026年，品牌學名藥市場規模將達到4.051億美元，到2033年將達到6.72億美元。預計從2026年到2033年，其複合年成長率將達到7.5%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 4.051億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 7.50% | 2033年市場規模預測： | 6.72億美元 |
品牌非專利是指原廠藥生產商或學名藥生產商在專利到期後生產的學名藥。品牌非專利必須經過簡化的新藥申請（ANDA）程序才能上市。品牌非專利比相應的原廠藥便宜，但可能比該藥的普通學名藥貴。品牌非專利的定義是：由非原廠藥生產商生產的已失效原研藥的新劑型，或帶有原研藥名稱的專利到期產品的分子複製品。品牌非專利也可能是經過FDA已通過核准的原廠藥的不同鹽類。
品牌非專利和已獲批准的非專利經常被混淆，但它們並不相同。品牌非專利與其他學名藥一樣，在品牌藥專利到期後，需要經過美國食品藥品監督管理局（FDA）的核准流程。而已核准的非專利則是由品牌藥的生產商根據與原品牌藥相同的新藥認證（NDA）進行生產，並且可以在原品牌藥專利到期前銷售。
市場動態
ANDA（簡略新藥申請）核准數量的增加是市場成長的主要驅動力。根據德里藥學與研究大學於2023年3月7日發表的報導，2022年總合批准了742項ANDA申請，年增17%。此外，也批准了136項臨時申請，也超過了2021年的數字（117項），與最終ANDA核准數量相近。印度公司在今年獲批數量的成長中佔據主導地位，比前一年增加了88項。此外，品牌非專利藥價格的下降也導致了學名藥需求的激增。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球品牌非專利市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品等級改進、市場擴張和行銷策略做出明智的決策。
- 全球品牌學名藥市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
- 相關人員可以透過利用各種用於分析全球品牌非專利市場的策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
第4章 全球品牌學名藥市場：依藥物類別分類，2021-2033年
- 烷化劑
- 抗代謝物
- 荷爾蒙藥物
- 抗高血壓藥物
- 降血脂藥物
- 抗憂鬱症
- 抗精神病藥物
- 抗癲癇藥物
- 其他
第5章 全球品牌學名藥市場：依劑型分類，2021-2033年
- 口服
- 腸外
- 外用
- 其他
第6章 全球品牌學名藥市場：依適應症分類，2021-2033年
- 腫瘤學
- 心血管疾病
- 糖尿病
- 神經病學
- 消化系統疾病
- 皮膚病
- 止痛藥和抗發炎藥
- 其他
第7章 全球品牌學名藥市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
- 藥局
第8章 全球品牌學名藥市場：按地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- Mylan NV
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Aspen Pharmacare Holding Ltd.
- Abbott Laboratories
- Valeant Pharmaceuticals International, Inc.
第10章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI3391
Branded Generics Market is estimated to be valued at USD 405.1 Mn in 2026 and is expected to reach USD 672.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 405.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 672.0 Mn |
Branded generic is a generic drug, which is manufactured by either original manufacturer after patent expiry of the brand, or is manufactured by a generic manufacturer. Branded generic has to go through abbreviated new drug application (ANDA) process before it can be marketed. Branded generic are cheaper than their branded counterparts but can be costlier than generic versions of the drug. Branded generic is defined as a product that is a novel dosage form of a branded off-patent medicine, and is manufactured by a different manufacturer than originator, or a molecule copy of an off-patent product with a trade name. Branded generics can also be different salts of an FDA-approved brand name drug.
It is easy to confuse branded generics with authorized generics, but they are not the same. Branded generics go through the same FDA approval process as other generics after branded drug patents expire. Authorized generics, however, are created by makers of branded drugs, under the same NDA (New Drug Approval) authorization as the original branded drug, and they may be sold before drug patents expire.
Market Dynamics
Rising ANDA approvals is a major factor which is supporting the market growth. According to an article published by Delhi Pharmaceutical Sciences & Research University on March 7 2023, a total of 742 Abbreviated New Drug Application (ANDA) approvals were granted during the calendar year 2022, registering a growth of 17% over last year. Additionally, 136 Tentative Approvals were also granted, again a similar growth over 2021 numbers (117) as seen for final ANDA approvals. Indian players contributed a large proportion of the incremental number of approvals this year with 88 more approvals than last year. Additionally, demand for generic medications is in surge owing to the affordable prices of branded generics.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global branded generics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Aspen Pharmacare Holding Ltd., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global branded generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global branded generics market.
Detailed Segmentation:
- Global Branded Generics Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptics
- Others
- Global Branded Generics Market, By Formulation (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Topical
- Others
- Global Branded Generics Market, By Indication (Revenue, USD Mn, 2021 - 2033)
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics and Anti-inflammatory
- Others
- Global Branded Generics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Branded Generics Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Mylan N.V
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Aspen Pharmacare Holding Ltd.
- Abbott Laboratories
- Valeant Pharmaceuticals International, Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Formulation
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Branded Generics Market, By Drug Class, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Alkylating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Anti-Hypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Lipid Lowering Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Anti-Depressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Anti-Psychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Anti-Epileptics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
5. Global Branded Generics Market, By Formulation, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Branded Generics Market, By Indication, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Gastrointestinal Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Dermatology Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Analgesics and Anti-inflammatory
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Global Branded Generics Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Drug Stores
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
8. Global Branded Generics Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Mylan N.V
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aspen Pharmacare Holding Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Valeant Pharmaceuticals International, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
02-2729-4219
+886-2-2729-4219
品牌學名藥市場：按劑型、治療領域、應用和分銷管道分類－2026-2032年全球市場預測
2026-2034年全球已通過核准學名藥市場規模、佔有率、趨勢和成長分析報告品牌學名藥市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026年至2034年預測已批准學名藥市場規模、佔有率、成長、全球產業分析、區域趨勢以及 2026 年至 2034 年的預測。
品牌非專利市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、應用、分銷管道、地區和競爭格局分類，2021-2031年2026-2034年全球品牌學名藥市場規模、佔有率、趨勢和成長分析報告
品牌非專利市場規模、佔有率和趨勢分析報告：按藥物類別、應用、給藥途徑、分銷管道、地區和細分市場預測，2026-2033年2026 年至 2032 年品牌非專利市場（依藥品類別、用途、給藥途徑、通路及地區分類）